HealthShares Emerging Cancer
was Thursday's best performer among exchange-traded funds, as positive headlines out of holding
boosted the ETF by more than 4%.
Dendreon jumped 43% after the biotech company said the Food and Drug Administration provided confirmation it will accept either a positive interim or final analysis of survival in order to approve the prostate cancer vaccine, Provenge.
The HealthShares Emerging Cancer ETF was recently up 96 cents, or 4.1%, to $24.49.
ETFs tracking silver and gold were also among the best performers. Silver futures surged by 29 cents to $13.51 an ounce. Gold futures were adding $5.80 to $665.10 an ounce.
PowerShares DB Silver
ETF was climbing 61 cents, or 2.6%, to $26.49. The
iShares Silver Trust
was up $2.60, or 2.3%, to $133.61. The
streetTRACKS Gold Shares
rose 67 cents, or 1.7%, to $38.66.
Internet Infrastructure HOLDRs
was also rising. Among its holdings,
was rising 2.1%, and
was up 3.9%.
The Internet Infrastructure HOLDRs ETF was recently adding 10 cents, or 1.7%, to $5.41.
Housing-related ETFs were among few losers Thursday. Among housing concerns,
was shedding 1.8%,
was losing 1.6% and
was lower by 1%.
iShares Dow Jones U.S. Home Construction
ETF was recently falling by 29 cents, or 0.8%, at $37.16. The
ETF was down 13 cents, or 0.5%, to $35.57.